Literature DB >> 1627805

The low risk of hepatitis C virus transmission among sexual partners of hepatitis C-infected hemophilic males: an international, multicenter study.

D B Brettler1, P M Mannucci, A Gringeri, J E Rasko, A D Forsberg, M G Rumi, R J Garsia, K A Rickard, M Colombo.   

Abstract

To study the transmission rate of hepatitis C virus (HCV) in the female sexual partners of antibody-positive hemophilic males, 106 partners from three hemophilia centers located in Europe, America, and Australia were tested for HCV seropositivity using a first-generation enzyme-linked immunosorbent assay (ELISA-1) and, subsequently, a second-generation ELISA (ELISA-2) and a supplemental recombinant immunoblot assay. Additionally, the cohort was tested for the presence of antibody to the human immunodeficiency virus type-1 and hepatitis B virus markers. No female partner was HCV antibody-positive using the ELISA-1 test, whereas five were seropositive by the ELISA-2 test. Three of these five female partners were seropositive on the supplemental test, the remaining two having indeterminate results, for an overall prevalence of 2.7%. Thus, even with the use of sensitive testing, the prevalence of HCV infection remains low in this cohort, showing that the efficiency of heterosexual transmission of HCV is poor.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1627805

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  26 in total

1.  Hepatitis C virus serotypes and sources of infection in patients with HCV-related chronic liver disease from one geographical area in southeast Italy.

Authors:  P Dentico; N Curatolo; R Sacco; M De Luca; A Volpe; C Ranieri; C Genchi; L Petracca; R Buongiorno
Journal:  Infection       Date:  1999 Mar-Apr       Impact factor: 3.553

2.  A study on the role of the family and other risk factors in HCV transmission.

Authors:  S Brusaferro; F Barbone; P Andrian; G Brianti; L Ciccone; A Furlan; D Gnesutta; S Stel; E Zamparo; P Toniutto; P Ferroni; V Gasparini
Journal:  Eur J Epidemiol       Date:  1999-02       Impact factor: 8.082

Review 3.  Reciprocal interaction of human immunodeficiency virus and hepatitis C virus infections.

Authors:  K E Nelson; D L Thomas
Journal:  Clin Diagn Lab Immunol       Date:  2001-09

4.  Exposure to low infective doses of HCV induces cellular immune responses without consistently detectable viremia or seroconversion in chimpanzees.

Authors:  Mohamed Tarek Shata; Nancy Tricoche; Marion Perkus; Darley Tom; Betsy Brotman; Patricia McCormack; Wolfram Pfahler; Dong-Hun Lee; Leslie H Tobler; Michael Busch; Alfred M Prince
Journal:  Virology       Date:  2003-09-30       Impact factor: 3.616

Review 5.  Hepatitis C virus infection in the elderly. Epidemiology, prophylaxis and optimal treatment.

Authors:  J Hayashi; S Kashiwagi
Journal:  Drugs Aging       Date:  1997-10       Impact factor: 3.923

6.  Sexually transmitted diseases treatment guidelines, 2015.

Authors:  Kimberly A Workowski; Gail A Bolan
Journal:  MMWR Recomm Rep       Date:  2015-06-05

7.  Identifying and describing a cohort effect in the national database of reported cases of hepatitis C virus infection in Canada (1991-2010): an age-period-cohort analysis.

Authors:  Max Trubnikov; Ping Yan; Jane Njihia; Chris Archibald
Journal:  CMAJ Open       Date:  2014-10-01

8.  Incidence and morbidity of infection by hepatitis C virus in children with acute lymphoblastic leukaemia.

Authors:  S P Dibenedetto; R Ragusa; A Sciacca; A Di Cataldo; V Miraglia; S D'Amico; L Lo Nigro; A M Ippolito
Journal:  Eur J Pediatr       Date:  1994-04       Impact factor: 3.183

Review 9.  Incidence of sexually transmitted hepatitis C virus infection in HIV-positive men who have sex with men.

Authors:  Holly Hagan; Ashly E Jordan; Joshua Neurer; Charles M Cleland
Journal:  AIDS       Date:  2015-11       Impact factor: 4.177

Review 10.  Managing occupational risks for hepatitis C transmission in the health care setting.

Authors:  David K Henderson
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.